In Vitro Biochemical Study of CYP51-Mediated Azole Resistance in Aspergillus fumigatus
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The incidence of triazole-resistant Aspergillus infections is increasing worldwide, often mediated through mutations in the CYP51A amino acid sequence. New classes of azole-based drugs are required to combat the increasing resistance to existing triazole therapeutics. In this study, a CYP51 reconstitution assay is described consisting of eburicol, purified recombinant Aspergillus fumigatus CPR1 (AfCPR1), and Escherichia coli membrane suspensions containing recombinant A. fumigatus CYP51 proteins, allowing in vitro screening of azole antifungals. Azole-CYP51 studies determining the 50% inhibitory concentration (IC 50) showed that A. fumigatus CYP51B (Af51B IC 50, 0.50 μM) was 34-fold more susceptible to inhibition by fluconazole than A. fumigatus CYP51A (Af51A IC 50, 17 μM) and that Af51A and Af51B were equally susceptible to inhibition by voriconazole, itraconazole, and posaconazole (IC 50 s of 0.16 to 0.38 μM). Af51A-G54W and Af51A-M220K enzymes were 11- and 15-fold less susceptible to inhibition by itraconazole and 30- and 8-fold less susceptible to inhibition by posaconazole than wild-type Af51A, confirming the azole-resistant phenotype of these two Af51A mutations. Susceptibility to voriconazole of Af51A-G54W and Af51A-M220K was only marginally lower than that of wild-type Af51A. Susceptibility of Af51A-L98H to inhibition by voriconazole, itraconazole, and posaconazole was only marginally lower (less than 2-fold) than that of wild-type Af51A. However, Af51A-L98H retained 5 to 8% residual activity in the presence of 32 μM triazole, which could confer azole resistance in A. fumigatus strains that harbor the Af51A-L98H mutation. The AfCPR1/Af51 assay system demonstrated the biochemical basis for the increased azole resistance of A. fumigatus strains harboring G54W, L98H, and M220K Af51A point mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490 · cited 1×
“The TR34 tandem repeat modification of the Af51A promoter region also caused a 5to 8-fold increase in Af51A expression levels (10, 45).”
Backgroundvan der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342 · cited 2×
“Clinical applications include assessing the likely impact of new emergent Af51A mutations, such as TR46/ Y121F/T289A (8), on the azole susceptibility of A. fumigatus strains that harbor the mutations.”
BackgroundMellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2747-2750.2004 · Cited by 210
Pfaller, M., Boyken, L., Hollis, R., Kroeger, J., Messer, S., Tendolkar, S., & Diekema, D. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02136-10 · Cited by 91
Warrilow, A. G. S., Melo, N., Martel, C. M., Parker, J. E., Nes, W. D., Kelly, S. L., & Kelly, D. E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00316-10 · Cited by 85
Self-citationAzole Antifungal Resistance Today: Focus on Aspergillus
Bowyer, P., Moore, C. B., Rautemaa, R., Denning, D. W., & Richardson, M. D. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0218-4 · Cited by 44 · cited 3×
“Point mutations at G54 are associated with reduced susceptibility toward itraconazole and posaconazole without loss of susceptibility to voriconazole (37), reflected in significantly increased MICs for itraconazole and posaconazole (Table 3) (38, 39).”
Background
Cited by
Rybak, J. M., Ge, W., Wiederhold, N. P., Parker, J. E., Kelly, S. L., Rogers, P. D., & Fortwendel, J. R. (2019) · mBio · doi:10.1128/mbio.00437-19 · Cited by 130
“0) for 24 h before cells were flash frozen with liquid nitrogen, dry weights were obtained, and nonsaponifiable lipids were extracted, derivatized, and analyzed by gas chromatography-mass spectrometry as described previously (46, 47).”
MethodSelf-citationDudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
Colley, T., Alanio, A., Kelly, S. L., Sehra, G., Kizawa, Y., Warrilow, A. G. S., Parker, J. E., Kelly, D. E., Kimura, G., Anderson-Dring, L., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02280-16 · Cited by 87
Self-citationEmerging threat of triazole-resistant Aspergillus fumigatus
Rybak, J. M., Fortwendel, J. R., & Rogers, P. D. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky517 · Cited by 80
Valero, C., Colabardini, A. C., de Castro, P. A., Amich, J., Bromley, M. J., & Goldman, G. H. (2022) · mBio · doi:10.1128/mbio.00447-22 · Cited by 23
“ERG11) (8), CAS acts by noncompetitively inhibiting the fungal b-1,3-glucan synthase (Fks1), which is essential for the biosynthesis of b-1,3-glucan in the fungal cell wall (9).”
Background
Metadata
- Authors
- Warrilow, A. G. S., Parker, J. E., Price, C. L., Nes, W. D., Kelly, S. L., & Kelly, D. E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-12
- Volume
- 59
- Issue
- 12
- Pages
- 7771-7778
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2352140081
- Cited by
- 38
- References
- 6
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vitro Biochemical Study of CYP51-Mediated Azole Resistance in Aspergillus fumigatus. https://app.cochat.ai/papers/10.1128/aac.01806-15
- The paper
- Warrilow, A. G. S., Parker, J. E., Price, C. L., Nes, W. D., Kelly, S. L., & Kelly, D. E. (2015). In Vitro Biochemical Study of CYP51-Mediated Azole Resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01806-15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.